Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 10/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | HTT | P42858 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1659816 | 0.85 | MAPT (0.62) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL1659812 | 0.85 | MAPT (0.62) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL17903202 | 0.83 | KMT2A (0.70) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL13100734 | 0.81 | MAPT (0.62) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL13942699 | 0.80 | KMT2A (0.77) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL1660591 | 0.79 | LMNA (0.68) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL1660585 | 0.79 | LMNA (0.68) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL29345068 | 0.79 | MAPT (0.64) | KMT2ASMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL11899414 | 0.79 | MAPT (0.64) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL11899415 | 0.79 | MAPT (0.64) | KMT2ASMN1; SMN2MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143030-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PKR-ASSOCIATED DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163666-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PKR-ASSOCIATED DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143030-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PKR-ASSOCIATED DISEASES | EIF2AK2, EIF2AK4, EIF2AK1 | KMT2A 1225/4885SMN1; SMN2 209/4885MAPT 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.